NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: POSSIBILITIES OF REDUCING BACK PAIN INTENSITY IN PATIENTS WITHOSTEOPOROSIS
https://doi.org/10.14412/1996-7012-2009-538
Abstract
Objective: to evaluate the efficiency and tolerability of a 10-day course of therapy with different doses of meloxicam in patients with osteoporosis and back pain.
Subjects and methods. The study covered 60 women (mean age 70±7 years), who were randomized to 3 groups: those who received meloxicam in doses of 15 and 7,5 mg and controls.
Results. During 10-day therapy, there was a significant reduction in the intensity of back pain when meloxicam was given in doses of
both 7,5 mg and 15 mg/day (p < 0,001) as compared with the baseline level and in the control group (p < 0,05). At the same time, the pain syndrome became insignificantly lower in the control group following 10 days (p > 0,05). In the first 2 groups, movement restriction significantly reduced, as well as physical activity increased and health improved, as rated by the Oswestry and EQ-5D questionnaires. Improvement was recorded in 27 (67,5%) patients, a satisfactory effect was seen in 10 (25%), there was no effect in 3 (7,5%) women.
Conclusion. The treatment was generally well tolerated.
Subjects and methods. The study covered 60 women (mean age 70±7 years), who were randomized to 3 groups: those who received meloxicam in doses of 15 and 7,5 mg and controls.
Results. During 10-day therapy, there was a significant reduction in the intensity of back pain when meloxicam was given in doses of
both 7,5 mg and 15 mg/day (p < 0,001) as compared with the baseline level and in the control group (p < 0,05). At the same time, the pain syndrome became insignificantly lower in the control group following 10 days (p > 0,05). In the first 2 groups, movement restriction significantly reduced, as well as physical activity increased and health improved, as rated by the Oswestry and EQ-5D questionnaires. Improvement was recorded in 27 (67,5%) patients, a satisfactory effect was seen in 10 (25%), there was no effect in 3 (7,5%) women.
Conclusion. The treatment was generally well tolerated.
References
1. <div><p>McLean S.A., Majo R.F., Domeier R.M. The epidemiology of pain in the prehospital setting. Prehosp Emerg Care 2002;6(4):402-5.</p><p>Руководство по остеопорозу. Под ред. Л.И. Беневоленской. М.: Бином, 2003.</p><p>Клинические рекомендации. Остеопороз. Диагностика, профилактика и лечение. Под ред. Л.И. Беневоленской и О.М. Лесняк. М.: ГЭОТАР-Медиа, 2009.</p><p>Рожинская Л.Я. Системный остеопороз. Практическое руководство для врачей. М.: Издатель Мокеев, 2000.</p><p>Насонов Е.Л., Цветкова Е.С. Селективные ингибиторы циклооксигеназы-2: новые перспективы лечения заболеваний человека. Тер арх 1998;5:8-14.</p><p>Насонов Е.Л. Применение нестероидных противовоспалительных препаратов и ингибиторов циклооксигеназы-2 в начале XXI века. РМЖ 2003;7:375-9.</p></div><br />
Review
For citations:
Toroptsova NV, Korotkova TA, Nikitinskaya OA. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: POSSIBILITIES OF REDUCING BACK PAIN INTENSITY IN PATIENTS WITHOSTEOPOROSIS. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2009;3(2):37-42. (In Russ.) https://doi.org/10.14412/1996-7012-2009-538
Views:
1942
Email this article 